Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SSY Group ( (HK:2005) ) has provided an update.
SSY Group Limited has announced that its Low Calcium Peritoneal Dialysis Solution has passed the Consistency Evaluation of the Quality and Efficacy of Generic Drugs by the National Medical Products Administration of China. This development marks a significant advancement for the company, enhancing its product offerings in the treatment of renal failure and potentially strengthening its position in the pharmaceutical market.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the healthcare industry, focusing on the development and production of pharmaceutical products. The company specializes in generic drugs, with a market focus on providing medical solutions for patients with renal failure.
Average Trading Volume: 7,548,251
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.88B
For detailed information about 2005 stock, go to TipRanks’ Stock Analysis page.